Ballesteros-Pomar María Dolores, Rodríguez-Urgellés Ened, Sastre-Belío Miquel, Martín-Lorenzo Alberto, Schnecke Volker, Segú Lluís, Brosa Max, Vilarrasa Nuria
Department of Endocrinology and Nutrition, Complejo Asistencial Universitario de León, Altos de Nava S/N, 24701, León, Spain.
Market Access & Healthcare Consulting, Cencora PharmaLex Spain, C/del Comte d'Urgell, 240, 2D, 08036, Barcelona, Spain.
Adv Ther. 2025 Feb;42(2):1265-1282. doi: 10.1007/s12325-024-03094-3. Epub 2025 Jan 18.
Obesity and its complications are associated with high morbidity/mortality and a significant healthcare cost burden in Spain. It is therefore essential to know the potential clinical and economic benefits of reducing obesity. The objective of this study is to predict the decrease in rates of onset of potential complications associated with obesity and the cost savings after a weight loss of 15% over 10 years in Spain.
Data were combined in an adapted version of a weight loss benefit simulation model. Sources with demographic information on the Spanish population and the distribution of obesity and type 2 diabetes mellitus (T2DM) were used to obtain the data for the model. In addition, use was made of prevalence data on obesity-associated complications from a cohort of patients with obesity in the United Kingdom (UK). These data were combined by age and sex to create a Spanish synthetic cohort.
The simulation showed that, for a cohort of 100,000 individuals with a body mass index (BMI) of 30-50 kg/m, a weight loss of 15% is estimated to lead to relevant relative risk reductions in obstructive sleep apnoea (OSA) (- 56.4%), T2DM (- 39.2%), asthma (- 20.2%) and arterial hypertension (- 18.7%). The estimated overall savings were €105 million for a cohort of 100,000 individuals, mainly resulting from the decrease in T2DM and arterial hypertension (23% and 22% of the total savings at year 10, respectively), as well as osteoarthritis and chronic kidney disease (CKD) (16% and 13%, respectively).
Sustained weight loss could significantly reduce the burden derived from future complications associated to obesity in Spain, as well as the excess economic cost associated with its treatment.
肥胖及其并发症与西班牙的高发病率/死亡率以及巨大的医疗成本负担相关。因此,了解减轻肥胖的潜在临床和经济效益至关重要。本研究的目的是预测西班牙肥胖相关潜在并发症发病率的下降情况以及10年内体重减轻15%后的成本节约情况。
数据被整合到一个经过调整的减肥效益模拟模型中。使用有关西班牙人口的人口统计学信息以及肥胖和2型糖尿病(T2DM)分布的数据源来获取模型数据。此外,还利用了英国一组肥胖患者中肥胖相关并发症的患病率数据。这些数据按年龄和性别进行合并,以创建一个西班牙合成队列。
模拟显示,对于100,000名体重指数(BMI)为30 - 50 kg/m²的个体队列,估计体重减轻15%会使阻塞性睡眠呼吸暂停(OSA)(-56.4%)、T2DM(-39.2%)、哮喘(-20.2%)和动脉高血压(-18.7%)的相关相对风险降低。对于100,000名个体的队列,估计总体节约成本为1.05亿欧元,主要源于T2DM和动脉高血压的减少(分别占第10年总节约成本的23%和22%),以及骨关节炎和慢性肾脏病(CKD)(分别为16%和13%)。
持续体重减轻可显著减轻西班牙肥胖相关未来并发症带来的负担以及与其治疗相关的额外经济成本。